Health Care • Biotechnology: Pharmaceutical Preparations
$82.84 ▼ -0.36
(-0.43%)
MKT CAP: $3.68B • VOL: 688.4K
52W L $40 52W H $100
IRON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$236.0M | -$129.7M | -$91.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$212.2M | -$109.4M | -$76.4M |
| EBITDA (Normalized) | -$235.3M | -$129.3M | -$91.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$180.4M | -$93.9M | -$73.5M |
| Capital Expenditures (CapEx) | $933.0K | $505.0K | $0 |
| Free Cash Flow (FCF) | -$181.3M | -$94.4M | -$73.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -27.5% | -37.3% | -5.9% |
| Cash & Short-Term Equivalents | $91.1M | $192.4M | $222.5M |
| Total Debt (Short + Long Term) | $30.2M | $23.9M | $473.3M |
| Total Stockholders' Equity | $739.8M | $443.6M | $970.9M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRON.